LDC, a private equity firm, completed the acquisition of a minority stake in TMC Pharma Services, a pharmaceutical development organisation, for £18m. “Our unique business model has worked outstandingly well over the last 20 years, including navigating a challenging COVID period successfully. We have been delighted to help many clients to bring valuable treatments to patients, especially those with Rare and Orphan Diseases with few therapy options. Now, with LDC’s support we are entering an exciting next phase, where we will further strengthen our team, and expand our global reach, for the benefit of patients with unmet medical needs, our clients and for our staff and Associates," Julie Matthews, TMC Pharma Services CEO.